Skip to content

Primary prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive behaviour programme aimed at lifestyle changes in people with abdominal obesity.

Primary prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive behaviour programme aimed at lifestyle changes in people with abdominal obesity.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28000
Enrollment
600
Registered
2007-02-08
Start date
2007-08-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention, lifestyle, Cognitive behavior treatment, diabetes mellitus type 2, cardiovascular disease. Preventie, leefstijl, cognitief gedragsprogramma, diabetes mellitus type 2, hart- en vaatziekten

Interventions

The intervention group will receive a cognitive behavior program (CBP) consisting of Motivational Interviewing and Problem Solving Treatment, a program that in particular is focused on motivation and

Sponsors

G.Nijpels
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Persons aged 30-50; 2. With a moderate or high risk of CVD (as calculated according to the SCORE-project); 3. Or a high risk of DM2 (as calculated according to the risk function of the ARIC Study").

Exclusion criteria

Exclusion criteria: 1. Having diabetes 2. Previous CVD; 3. Pregnancy; 4. Current malignant disease; 5. (Severe) Mobility problems.

Design outcomes

Primary

MeasureTime frame
1. Changes in cardiovascular risk score (risk function developed by the SCORE-project); 2. Changes in diabetes risk calculation (risk function from data of the ARIC Study);

Secondary

MeasureTime frame
1. Changes in lifestyle factors: a. dietary behaviour; b. physical activity; c. smoking behaviour; 2. Changes in perceived health; 3. Changes in medical care utilization; 4. Changes in waist circumference. 5. Cost effectiveness and cost-utility (costdiary and Euroqol).

Contacts

Public ContactJ. Lakerveld

VUmc-EMGO Afd. Huisartsgeneeskunde

j.lakerveld@vumc.nl+31 20 444 8167

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)